Spotlight On... Glycomics oral care company Prisyna nabs $6M to gain FDA device nod; Medtronic registry data bests trial in aortic repair; Liquid biopsy, mHealth make disruptive cancer tech list;

The oral care business of glycomics biotech Synedgen, Prisyna, has raised $6 million to back its oral rinse products. These include two marketed oral rinses, Synedent Oral Care and Synedent Plus Oral Care with fluoride, as well as the investigational Moistagen. The latter is a potential treatment for dry mouth, with a new formulation expected to relieve the symptoms of oral mucositis due to chemotherapy or radiation treatments. "The pain, discomfort and quality of life issues associated with dry mouth negatively impact millions of patients in the U.S. and I welcomed the opportunity to evaluate a new technology to address this oral health challenge," said Joel Epstein of Cedars-Sinai Medical Center in a statement. "The results of the Moistagen study showed the product's excellent ability to safely address the issues associated with dry mouth, especially among those patients who have pain and complications due to the accumulation of sticky mucus deposits." Synedgen discovers and develops polysaccharide-based drugs. Release

> Medtronic ($MDT) has reported data comparing a registry study with a trial on the Endurant AAA stent graft system for endovascular aortic repair (EVAR). It found lower rates of aneurysm-related mortality and rupture rates in the registry data. More

> Partners Healthcare, a system that includes Brigham and Women's Hospital and Massachusetts General Hospital, released its annual list of most disruptive technologies in cancer care. Liquid biopsy and mobile health devices both made the list. More

> Medtronic has released two-year data for its VenaSeal Closure System to treat venous reflux disease that shows long-term durability and improved quality of life. More